Aim To explore the clinical efficacy and safety of edaravone in the treatment of hypertensive cerebral hemorrhage. Methods From January,2011 to June,2014 in our hospital according to the experimental conditions,190 cases of hypertension cerebral hemorrhage were chosen and randomly divided into two groups: edaravone group （95 cases） and control group （95 cases）,the two groups had the base treatment,the neural function defect scale （NIHSS score）,daily life activities ability score （ADL score） and hematoma volume size were recorded and serum C- reactive protein （CRP） concentration was measured,at the same time the adverse reaction was observed in 14 days,21 days before and after treatment.